Godsey & Gibb Inc’s SELLAS Life Sciences SLS Stock Holding History

Godsey & Gibb Inc’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4	Closed	-$9	–	395
2022 Q4	$9	Buy	+4	New	+$11	﹤0.01%	302

Other funds holding SLS

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Equitable Holdings New York $16.7B AUM 24.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

OCG

Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Godsey & Gibb Inc's SLS Position: Q1 2023 in Review

Godsey & Gibb Inc sold out of SELLAS Life Sciences (SLS) in Q1 2023, closing a stake of 4 shares — an estimated $9 sold.

Godsey & Gibb Inc first reported a position in SLS in Q4 2022 and held it in 1 quarter. The position peaked at $9 in Q4 2022. 22 funds tracked by Wall St. Rank hold SLS as of Q1 2023.

Godsey & Gibb Inc reported no remaining SELLAS Life Sciences position as of Q1 2023 after selling out during the quarter.
Godsey & Gibb Inc sold 4 SELLAS Life Sciences shares in Q1 2023, an estimated $9.
Godsey & Gibb Inc first reported a position in SELLAS Life Sciences in Q4 2022 and held it in 1 quarter.
Godsey & Gibb Inc's SELLAS Life Sciences position peaked at $9 in Q4 2022.
22 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2023.

Based on Godsey & Gibb Inc's 13F filing for Q1 2023, filed 18 Apr 2023.